Skip to main navigation Skip to search Skip to main content

Stroke genetics informs drug discovery and risk prediction across ancestries

  • The INVENT Consortium
  • , The Dutch Parelsnoer Initiative (PSI) Cerebrovascular Disease Study Group
  • , The Estonian Biobank
  • , The PRECISEQ Consortium
  • , The FinnGen Consortium
  • , The NINDS Stroke Genetics Network (SiGN)
  • , The MEGASTROKE Consortium
  • , The SIREN Consortium
  • , The China Kadoorie Biobank Collaborative Group
  • , The VA Million Veteran Program
  • , The International Stroke Genetics Consortium (ISGC)
  • , The Biobank Japan
  • , The CHARGE Consortium
  • , The GIGASTROKE Consortium
  • , Regeneron Genetics Center
  • , The ODYSSEY Study
  • , HUNT All-In Stroke
  • , The SICFAIL Study
  • , The Generacion Study
  • , The Copenhagen City Heart Study
  • The SMART Study, Clinical Research Collaboration for Stroke in Korea (CRCS-K) and Korea Biobank Array (KBA) Project, Helsinki Stroke Project, Follow-up Studies, EPIC-CVD, The COMPASS Consortium
  • Institut national de la santé et de la recherche médicale
  • Ludwig Maximilian University of Munich
  • Iwate Medical University
  • University of Tartu
  • University of Tartu
  • The University of Osaka
  • Department of Veterans Affairs
  • Brigham and Women’s Hospital
  • Harvard University
  • The University of Tokyo
  • Massachusetts General Hospital
  • The Broad Institute of MIT and Harvard
  • Chung Shan Medical University
  • University of Turku
  • National Institute for Health and Welfare
  • University of Oxford
  • University of Oslo
  • Norwegian University of Science and Technology
  • University of Alabama at Birmingham
  • Seoul National University
  • Rajendra Institute of Medical Sciences
  • Thrombosis and Atherosclerosis Research Institute
  • McMaster University
  • Helsinki University Hospital
  • University of Ibadan
  • Erasmus University Rotterdam
  • Hebrew University of Jerusalem
  • University of Copenhagen
  • Geisinger Medical Center
  • Pennsylvania State University
  • Research Institute of the Santa Creu i Sant Pau Hospital
  • Autonomous University of Barcelona
  • University of Southern Denmark
  • National Institutes of Health
  • Data Tecnica International
  • University of Virginia
  • University of Cambridge
  • Vanderbilt University
  • University of Pennsylvania
  • Kyushu University
  • University of Lille
  • Centre Hospitalier Universitaire de Lille
  • Institut Pasteur de Lille
  • Utrecht University
  • University of Washington
  • Rush University

Research output: Contribution to journalArticlepeer-review

442 Scopus citations

Abstract

Previous genome-wide association studies (GWASs) of stroke — the second leading cause of death worldwide — were conducted predominantly in populations of European ancestry1,2. Here, in cross-ancestry GWAS meta-analyses of 110,182 patients who have had a stroke (five ancestries, 33% non-European) and 1,503,898 control individuals, we identify association signals for stroke and its subtypes at 89 (61 new) independent loci: 60 in primary inverse-variance-weighted analyses and 29 in secondary meta-regression and multitrait analyses. On the basis of internal cross-ancestry validation and an independent follow-up in 89,084 additional cases of stroke (30% non-European) and 1,013,843 control individuals, 87% of the primary stroke risk loci and 60% of the secondary stroke risk loci were replicated (P < 0.05). Effect sizes were highly correlated across ancestries. Cross-ancestry fine-mapping, in silico mutagenesis analysis3, and transcriptome-wide and proteome-wide association analyses revealed putative causal genes (such as SH3PXD2A and FURIN) and variants (such as at GRK5 and NOS3). Using a three-pronged approach4, we provide genetic evidence for putative drug effects, highlighting F11, KLKB1, PROC, GP1BA, LAMC2 and VCAM1 as possible targets, with drugs already under investigation for stroke for F11 and PROC. A polygenic score integrating cross-ancestry and ancestry-specific stroke GWASs with vascular-risk factor GWASs (integrative polygenic scores) strongly predicted ischaemic stroke in populations of European, East Asian and African ancestry5. Stroke genetic risk scores were predictive of ischaemic stroke independent of clinical risk factors in 52,600 clinical-trial participants with cardiometabolic disease. Our results provide insights to inform biology, reveal potential drug targets and derive genetic risk prediction tools across ancestries.

Original languageEnglish
Pages (from-to)115-123
Number of pages9
JournalNature
Volume611
Issue number7934
DOIs
StatePublished - Nov 3 2022

Fingerprint

Dive into the research topics of 'Stroke genetics informs drug discovery and risk prediction across ancestries'. Together they form a unique fingerprint.

Cite this